Literature DB >> 32592623

Long-Term Disease Control Using Taxane/Platinum-Based Chemotherapy in CDK12-Mutated Advanced Prostate Cancer.

Pedro Barata1, Elisa Ledet1, Charlotte Manogue1, Patrick Cotogno1, Kendra Harris1, Brian Lewis1, Jodi Layton1, Oliver Sartor1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32592623      PMCID： PMC7485348          DOI： 10.1634/theoncologist.2020-0260

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  5 in total

1.  Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer.

Authors:  Emmanuel S Antonarakis
Journal:  N Engl J Med       Date:  2018-09-13       Impact factor: 91.245

2.  Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.

Authors:  Melissa A Reimers; Steven M Yip; Li Zhang; Marcin Cieslik; Mallika Dhawan; Bruce Montgomery; Alexander W Wyatt; Kim N Chi; Eric J Small; Arul M Chinnaiyan; Ajjai S Alva; Felix Y Feng; Jonathan Chou
Journal:  Eur Urol       Date:  2019-10-20       Impact factor: 20.096

3.  CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.

Authors:  Emmanuel S Antonarakis; Pedro Isaacsson Velho; Wei Fu; Hao Wang; Neeraj Agarwal; Victor Sacristan Santos; Benjamin L Maughan; Roberto Pili; Nabil Adra; Cora N Sternberg; Panagiotis J Vlachostergios; Scott T Tagawa; Alan H Bryce; Andrea L McNatty; Zachery R Reichert; Robert Dreicer; Oliver Sartor; Tamara L Lotan; Maha Hussain
Journal:  JCO Precis Oncol       Date:  2020-04-21

4.  Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer.

Authors:  Yu Wei; Junlong Wu; Weijie Gu; Jun Wang; Guowen Lin; Xiaojian Qin; Bo Dai; Hualei Gan; Dingwei Ye; Yao Zhu
Journal:  Oncologist       Date:  2020-03-19

5.  Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.

Authors:  Yi-Mi Wu; Marcin Cieślik; Robert J Lonigro; Pankaj Vats; Melissa A Reimers; Xuhong Cao; Yu Ning; Lisha Wang; Lakshmi P Kunju; Navonil de Sarkar; Elisabeth I Heath; Jonathan Chou; Felix Y Feng; Peter S Nelson; Johann S de Bono; Weiping Zou; Bruce Montgomery; Ajjai Alva; Dan R Robinson; Arul M Chinnaiyan
Journal:  Cell       Date:  2018-06-14       Impact factor: 41.582
  5 in total
  1 in total

Review 1.  PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.

Authors:  Emily N Risdon; Cindy H Chau; Douglas K Price; Oliver Sartor; William D Figg
Journal:  Oncologist       Date:  2020-09-08       Impact factor: 5.837
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.